Author(s)

Eurico Cleto Ribeiro de Campos^1*, Marcos Gonçalves Adriano Júnior¹, Marcus Rivabem Winheski², Ricardo Poroski², Diego Sanches², Robson Menezes Leal², Marcela Cavalcanti³, Emanuela Benevides Poyer⁴, Renan Martins⁵

¹Department of Melanoma and Soft Tissue Sarcoma from Prevent Senior Sao Paulo Group, Sao Paulo, Brasil.
²Oncology Surgical Department of Evangélico Mackenzie University Hospital, Curitiba, Paraná.
³Department of Pathology Neopath, Curitiba, Paraná, Brasil.
⁴Department of Clinical Oncology from Evangélico Mackenzie University Hospital.
⁵Ponta Grossa State University, Paraná, Brasil.

Clear Cell Sarcoma (CCS) is a rare soft tissue sarcoma that corresponds to a less than 1% of all sarcomas and is a high degree neoplasm with propensity to disseminate to regional lymph nodes. Regional lymphadenectomies have a controversial impact on sarcomas treatment and survival, even though those patients have higher local recurrence and lower survival. So, sentinel lymph node biopsy must be one option for better regional staging to STS with higher propensity to lymph node commitment. The authors demonstrate two cases of CCS submitted to surgery through compartmental resection associated with the sentinel lymph node biopsy. A literature review about soft tissue sarcoma and lymph node sentinel biopsy is shown as an initial experience of two cases.

Clear Cell Sarcomas, Soft Tissue Sarcoma, Sentinel Biopsy

de Campos, E. , Júnior, M. , Winheski, M. , Poroski, R. , Sanches, D. , Leal, R. , Cavalcanti, M. , Poyer, E. and Martins, R. (2020) Analysis of Sentinel Lymph Node Biopsy on Clear Cell Sarcoma Treatment. Journal of Cancer Therapy, 11, 785-792. doi: 10.4236/jct.2020.1112068.